Literature DB >> 19858926

Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.

Andrea Calcagno, Stefano Bonora, Maria Cristina Tettoni, Antonio D'Avolio, Giovanni Di Perri, Massimiliano Lanzafame, Giovanni Penco.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19858926     DOI: 10.1097/QAI.0b013e3181b08f09

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  4 in total

1.  Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.

Authors:  Alessandro Schipani; Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Marco Simiele; Stefano Bonora; Sonia Rodríguez Novoa; Lorena Cuenca; Vincent Soriano; Nitipatana Chierakul; Natpratou Saguenwong; Charoen Chuchuttaworn; Janelle M Hoskins; Anne M Dvorak; Howard L McLeod; Gerry Davies; Saye Khoo; David J Back; Giovanni Di Perri; Andrew Owen
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.

Authors:  Emanuele Focà; Diego Ripamonti; Davide Motta; Carlo Torti
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

3.  PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics.

Authors:  Maria Alvarellos; Chantal Guillemette; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2018-05       Impact factor: 2.089

4.  Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study.

Authors:  Laurent Hocqueloux; Philippe Choisy; Gwenaël Le Moal; Françoise Borsa-Lebas; David Plainchamp; Eric Legac; Thierry Prazuck; Xavier de la Tribonnière; Yazdan Yazdanpanah; Jean-Jacques Parienti
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.